NCT03501368 2026-02-27
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
H. Lee Moffitt Cancer Center and Research Institute
Roswell Park Cancer Institute
Novartis
Novartis
Novartis
Novartis
Novartis